BioTime Enters Into Agreement With Cell Cure and 2 Stocks Falling to 52-Week Lows

ADA-ES (NASDAQ:ADES): ADA-ES reported a third quarter earnings per share of 39c and a consensus of 1c. Their shares closed at $14.22, down $3.51 or 19.8% on the day. They have traded in a 52-week range of $14.71 to $29.83.

Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>

The Aes Corp. (NYSE:AES): The Aes Corp. reaffirmed their Proportional Free Cash Flow guidance range of $1.05-$1.25 billion. As previously disclosed in May, the company expects their Proportional Free Cash Flow to come in at the low end of the guidance range. Aes also reaffirmed their Subsidiary Distributions guidance range of $1.33-$1.53 billion.  As previously disclosed in August, they expect their Subsidiary Distributions to come in at the low end of the range, too. Their shares closed at $10.07, down $0.41 or 3.91% on the day. They have traded in a 52-week range of $10.34 to $14.01.

Biotime, Inc.(AMEX:BTX): BioTime, Inc. and their subsidiary, Cell Cure Neurosciences Ltd., announced that they have entered into a share purchase agreement in which they have agreed to purchase 87,456 Cell Cure ordinary shares in exchange for 906,735 BioTime common shares. As a result of this, BioTime will own, directly and through their wholly owned subsidiary, ES Cell International Pte. Ltd., approximately 62.6% of the outstanding ordinary shares of Cell Cure. Their shares closed at $3.47, down $0.2 or 5.45% on the day. They have traded in a 52-week range of $3.35 to $6.35.

Don’t Miss: Is Gold Set to Benefit from Obama’s Re-Election?